Press Releases Trevena, Inc.

Equities

TRVN

US89532E2081

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-02 pm EDT			5-day change	1st Jan Change
0.4095 ^USD	+6.70%		+7.48%	-43.29%

Apr. 01	Trevena, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Apr. 01	Trevena, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Trevena: Q4 Earnings Snapshot	Apr. 01	AQ
Trevena Reports Fourth Quarter 2023 Results and Provides Corporate Update	Apr. 01	AQ
Trevena : Reports Fourth Quarter 2023 Results and Provides Corporate Update - Form 8-K	Apr. 01	PU
Trevena Inc. Announces $4 Million Concurrent Private Placement and Warrant Exercise	Dec. 28	AQ
Trevena Inc. Announces $4 Million Concurrent Private Placement and Warrant Exercise	Dec. 27	AQ
Trevena Announces TRV045 Presentation at the American College of Neuropsychopharmacology 62nd Annual Meeting	Dec. 04	AQ
Trevena Awarded OLINVYK Agreement with Premier, Inc.	Dec. 04	AQ
Trevena Announces Acceptance of Abstract Examining the Use of OLINVYK in Patients with Acute Burn Injuries	Nov. 30	AQ
Trevena: Q3 Earnings Snapshot	Nov. 14	AQ
Trevena Reports Third Quarter 2023 Results and Provides Business Update	Nov. 14	AQ
Trevena : Management Change/Compensation - Form 8-K	Nov. 09	PU
Trevena to Release Third Quarter 2023 Financial Results on November 14, 2023	Nov. 09	AQ
Trevena Reports Favorable TRV045 Topline Safety and Tolerability Data from Proof-of-Concept Studies	23-10-16	AQ
Trevena Announces Completion of Initial Analysis of OLINVYK Continuous Respiratory Monitoring Data from VOLITION Study and Presentation at American Society of Anesthesiologists Conference	23-10-02	AQ
Thinking about buying stock in Plus Therapeutics, BioLine RX, Flora Growth, Emx Royalty, or Trevena?	23-09-11	PR
Trevena Announces Receipt of $15 Million Non-Dilutive Tranche and Provides General Business Update	23-09-06	AQ
Trevena Announces Preliminary TRV045 Data from Two Proof-of-Concept Studies Evaluating S1PR Mechanism of Action and CNS Target Engagement	23-09-06	AQ
Trevena: Q2 Earnings Snapshot	23-08-14	AQ
Trevena Reports Second Quarter 2023 Results and Provides Business Update	23-08-14	AQ
Trevena, Inc. Appoints Mark Corrigan, M.D. to Board of Directors	23-07-20	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Trevena, Inc.

Equities

TRVN

US89532E2081

Press Releases

Filters